SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms
16 references·0 citing·37 second hop
Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms (2012)Cost of Capital for Pharmaceutical, Biote…Is size dead? A review of the size effect in equity returns (2011)Is size dead? A review of the…Drug development costs when financial risk is measured using the Fama–French three‐factor model (2009)Drug development costs when f…The cost of biopharmaceutical R&D: is biotech different? (2007)The cost of biopharmaceutical…Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms (2007)Shareholder returns and the e…The Value Premium and the CAPM (2006)The Value Premium and the CAPMAn Examination of Long‐Term Abnormal Stock Returns and Operating Performance Following R&D Increases (2004)An Examination of Long‐Term A…Valuation and Return Dynamics of New Ventures (2003)Valuation and Return Dynamics…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …R&D Accounting and the Tradeoff Between Relevance and Objectivity (2002)R&D Accounting and the Tradeo…The Stock Market Valuation of Research and Development Expenditures (2001)The Stock Market Valuation of…The Stock Market Valuation of Research and Development Expenditures (2000)The Stock Market Valuation of…Penetrating the Book‐to‐Market Black Box: The R&D Effect (1999)Penetrating the Book‐to‐Marke…Common risk factors in the returns on stocks and bonds (1993)Common risk factors in the re…The Cross-Section of Expected Stock Returns (1992)The Cross-Section of Expected…Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…A New Look at the Returns and Risks to Pharmaceutical R&D (1990)A New Look at the Returns and…CAPITAL ASSET PRICES: A THEORY OF MARKET EQUILIBRIUM UNDER CONDITIONS OF RISK* (1964)Risk, Return, and Equilibrium: Empirical Tests (1973)Illiquidity and stock returns: cross-section and time-series effects (2002)A five-factor asset pricing model (2014)Principles of Corporate Finance. (1981)Deconstructing the Drug Development Process: The New Face of Innovation (2010)The cost of drug development: A systematic review (2011)Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017)The Modern Industrial Revolution, Exit, and the Failure of Internal Control Systems (1993)On Persistence in Mutual Fund Performance (1997)The Disposition Effect and Underreaction to News (2006)Stock market liquidity and firm value☆ (2009)Taming the Factor Zoo: A Test of New Factors (2020)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)Essential medicines for universal health coverage (2016)The Valuation of Risk Assets and the Selection of Risky Investments in Stock Portfolios and Capital Budgets (1965)Returns to Buying Winners and Selling Losers: Implications for Stock Market Efficiency (1993)Patents as Options: Some Estimates of the Value of Holding European Patent Stocks (1984)Patents as Options: Some Estimates of the Value of Holding European Patent Stocks (1986)Time to build, option value, and investment decisions (1987)Real Options, Product Market Competition, and Asset Returns (2009)Risk and Return Characteristics of Venture Capital-Backed Entrepreneurial Companies (2010)Product market competition, R&D investment, and stock returns (2015)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Excess Returns to R&D-Intensive Firms (2002)Separating Winners from Losers among LowBook-to-Market Stocks using Financial Statement Analysis (2005)Technological Links and Predictable Returns (2017)Market Reactions to Tangible and Intangible Information (2006)Innovative efficiency and stock returns (2012)Replicating Anomalies (2018)When Are Analyst Recommendation Changes Influential? (2009)Positive and Negative Corporate Social Responsibility, Financial Leverage, and Idiosyncratic Risk (2012)Comparing Asset Pricing Models (2018)
this work references cited by second hop

References

  • 1993Common risk factors in the returns on stocks and bonds26,615 cited
  • 1992The Cross-Section of Expected Stock Returns17,251 cited
  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 2001The Stock Market Valuation of Research and Development Expenditures1,734 cited
  • 2004An Examination of Long‐Term Abnormal Stock Returns and Operating Performance Following R&D Increases916 cited
  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 2006The Value Premium and the CAPM519 cited
  • 2007The cost of biopharmaceutical R&D: is biotech different?517 cited
  • 2000The Stock Market Valuation of Research and Development Expenditures455 cited
  • 2003Valuation and Return Dynamics of New Ventures311 cited
  • 2011Is size dead? A review of the size effect in equity returns302 cited
  • 1990A New Look at the Returns and Risks to Pharmaceutical R&D286 cited
  • 1999Penetrating the Book‐to‐Market Black Box: The R&D Effect253 cited
  • 2002R&D Accounting and the Tradeoff Between Relevance and Objectivity232 cited
  • 2009Drug development costs when financial risk is measured using the Fama–French three‐factor model108 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2007Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms91 cited
  • Cited by

    No citing works inside the corpus for this window.